According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “
A number of other equities research analysts have also commented on ACRS. JMP Securities assumed coverage on Aclaris Therapeutics in a research report on Friday. They set an outperform rating and a $34.00 price target on the stock. Jefferies Group raised their price target on Aclaris Therapeutics from $23.00 to $31.00 and gave the stock a buy rating in a research report on Monday, September 19th. Finally, Guggenheim assumed coverage on Aclaris Therapeutics in a research report on Friday, June 10th. They set a buy rating and a $35.00 price target on the stock. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company has an average rating of Buy and an average price target of $31.80.
Shares of Aclaris Therapeutics (NASDAQ:ACRS) opened at 25.61 on Friday. The company’s market cap is $548.44 million. The company has a 50 day moving average price of $22.46 and a 200 day moving average price of $20.11. Aclaris Therapeutics has a 52 week low of $10.99 and a 52 week high of $33.88.
Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Thursday, August 11th. The company reported ($0.62) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.01. On average, equities analysts expect that Aclaris Therapeutics will post ($2.60) earnings per share for the current year.
In other Aclaris Therapeutics news, insider Kamil Ali-Jackson sold 1,841 shares of the firm’s stock in a transaction that occurred on Wednesday, September 28th. The stock was sold at an average price of $24.66, for a total value of $45,399.06. Following the completion of the transaction, the insider now directly owns 77,798 shares in the company, valued at $1,918,498.68. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Ra Capital Management, Llc sold 525,550 shares of the firm’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $24.19, for a total value of $12,713,054.50. The disclosure for this sale can be found here. Corporate insiders own 46.40% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Nationwide Fund Advisors increased its position in Aclaris Therapeutics by 47.0% in the second quarter. Nationwide Fund Advisors now owns 5,747 shares of the company’s stock worth $106,000 after buying an additional 1,838 shares in the last quarter. Tocqueville Asset Management L.P. bought a new position in Aclaris Therapeutics during the second quarter worth $185,000. Teachers Advisors Inc. increased its position in Aclaris Therapeutics by 91.0% in the second quarter. Teachers Advisors Inc. now owns 14,212 shares of the company’s stock worth $262,000 after buying an additional 6,772 shares in the last quarter. Swiss National Bank bought a new position in Aclaris Therapeutics during the second quarter worth $283,000. Finally, Sabby Management LLC bought a new position in Aclaris Therapeutics during the second quarter worth $292,000. Hedge funds and other institutional investors own 71.39% of the company’s stock.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.